Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression

BACKGROUND: Novel therapies are needed for children with high-risk and relapsed neuroblastoma. We hypothesized that MAPK/ERK kinase (MEK) inhibition with the novel MEK1/2 inhibitor binimetinib would be effective in neuroblastoma preclinical models. METHODS: Levels of total and phosphorylated MEK and...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodfield, Sarah E., Zhang, Linna, Scorsone, Kathleen A., Liu, Yin, Zage, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772351/
https://www.ncbi.nlm.nih.gov/pubmed/26925841
http://dx.doi.org/10.1186/s12885-016-2199-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772351/
https://www.ncbi.nlm.nih.gov/pubmed/26925841
http://dx.doi.org/10.1186/s12885-016-2199-z

Ejemplares similares